Bullish Moving Averages
16
Bearish Moving Averages
0
Back Stocks profile
Stock analysis tool for investors
Open an Account with Bigul in 5 minutes
Performance
Today’s low
356.60Today’s High
365.9052W low
217.5052W High
365.90Open Price
357.20Prev. Close
332.7500Volume
6322027.00Value
2278458530.80Fundamentals
Market Cap Cr
43269.60
Price to Earnings
42.30
Price to Book Value
1.70
Dividend Yield
0.40
PE to Growth
0.30
Op Revenue TTM Cr
14755.70
Net Profit TTM Cr
1022.50
Cash From Operating Activity Cr
2953.90
Return on Equity %
5.16
EMA & SMA
DELIVERY AND VOLUME
DAILY AVG. DELIVERY VOLUME %
02 Jul, 2024
55.7
Week
42.7
Month
39
LEGEND
Positive Indicator
Neutral Indicator
Negative Indicator
RESISTANCE AND SUPPORT
357.70
PIVOT
First Resistance
360.90
Second Resistance
365.10
Third Resistance
368.30
First Support
353.50
Second Support
350.30
Third Support
346.10
Relative Strength Index
65.05
Money Flow Index
66.78
MACD
11.1
MACD Signal
10.26
Average True Range
11.68
Average Directional Index
22.03
Rate of Change (21)
15.34
Rate of Change (125)
42.88
Commodity Channel Index
128.7
Williams %R
-14.7
BETA
1 Month
0.93
3 Month
1
1 Year
0.98
3 Year
0.21
PRICE CHANGE ANALYSIS
↑ 6.23%
1 Week
Low
High
336.5
365.9
↑ 16.54%
1 Month
Low
High
269.55
365.9
↑ 33.46%
3 Months
Low
High
259.85
365.9
↑ 35.39%
6 Months
Low
High
244.55
365.9
↑ 35.74%
1 Year
Low
High
217.5
365.9
| Indicator | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Graph |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Qtr Revenue cr | 571.50 | 611.30 | 588.30 | 549.20 | 570.70 | 614.90 | 588.40 | 490.30 | 578.50 | 509.70 | 405.30 | |
| Operating Expenses Qtr | 480.40 | 491.50 | 451.50 | 441.20 | 550.70 | 517.90 | 461.70 | 439.10 | 491.20 | 438.70 | 388.00 | |
| Operating Profit Qtr | 52.20 | 71.30 | 67.20 | 72.00 | -44.00 | 37.10 | 27.80 | 2.60 | 26.50 | 34.30 | -23.20 | |
| EBIDT Qtr Cr | 91.10 | 119.80 | 131.60 | 127.70 | 1873.60 | 97.00 | 1135.90 | 51.20 | 87.30 | 71.00 | 17.30 | |
| Depreciation Qtr | 29.80 | 30.90 | 30.60 | 29.80 | 29.40 | 29.10 | 29.80 | 28.60 | 28.10 | 27.60 | 26.50 | |
| Net Profit Qtr | 14.00 | 24.00 | 34.70 | 46.60 | 1810.80 | 35.20 | 987.50 | 14.90 | 38.10 | 25.50 | -6.60 | |
| Basic EPS Qtr | 0.12 | 0.20 | 0.29 | 0.39 | 15.14 | 0.29 | 8.28 | 0.12 | 0.32 | 0.21 | -0.06 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total Revenue Annual | 2320.30 | 2264.30 | 1925.40 | 2178.60 | 2190.10 | |
| Operating Expenses Annual Cr | 1864.60 | 1969.40 | 1677.10 | 1715.90 | 1702.40 | |
| Operating Profit Annual | 262.70 | 23.50 | 61.10 | 312.50 | 286.00 | |
| Operating Profit Margin Annual % | 11.32 | 1.04 | 3.17 | 14.34 | 13.06 | |
| Total Expenses Annual Cr | 2184.50 | 2155.90 | 1785.70 | 1819.80 | 1801.60 | |
| EBIDT Annual Cr | 455.70 | 294.90 | 248.30 | 462.70 | 487.70 | |
| EBIDT Annual margin % | 19.64 | 13.02 | 12.90 | 21.24 | 22.27 | |
| Depreciation | 121.10 | 116.90 | 108.20 | 103.50 | 98.00 | |
| PAT Before ExtraOrdinary Items Annual Cr | 119.30 | 2848.40 | 86.10 | 280.50 | 436.30 | |
| Net Profit Annual | 119.30 | 2848.40 | 86.10 | 280.50 | 440.90 | |
| Basic EPS Annual | 1.00 | 23.87 | 0.72 | 2.36 | 3.72 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total ShareHolders Funds Annual | 10912.30 | 10916.00 | 8092.90 | 7907.10 | 7537.30 | |
| Minority Interest Liability Annual Cr | - | - | - | - | - | |
| Total Non Current Liabilities Annual Cr | 2164.70 | 1415.90 | 185.20 | 116.40 | 45.50 | |
| Total Current Liabilities Annual Cr | 691.20 | 698.00 | 590.90 | 550.20 | 728.00 | |
| Total Capital Plus Liabilities Annual Cr | 13768.20 | 13029.90 | 8869.00 | 8573.70 | 8310.80 | |
| Fixed Assets Annual | 1518.00 | 1304.90 | 1155.10 | 977.30 | 945.10 | |
| Total Non Current Assets Annual | 11008.20 | 10463.90 | 6466.80 | 6404.40 | 6227.10 | |
| Total Current Assets Annual | 2760.00 | 2566.00 | 2402.20 | 2169.30 | 2083.70 | |
| Total Assets Annual | 13768.20 | 13029.90 | 8869.00 | 8573.70 | 8310.80 | |
| Contingent Liabilities plus Commitments Annual Cr | - | 754.80 | 638.30 | 1749.60 | 2203.70 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Cash from Operating Activity Annual | -123.20 | 219.30 | 47.60 | 478.40 | 387.10 | |
| Cash from Investing Activity Annual | -296.40 | -1177.80 | -305.60 | -618.30 | -212.90 | |
| Cash from Financing Annual Activity | 343.60 | 1039.40 | 112.00 | 27.80 | -128.90 | |
| Net Cash Flow Annual | - | 80.90 | -146.00 | -112.10 | 45.30 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Book Value Per Share Annual | 90.89 | 90.91 | 67.40 | 65.89 | 62.80 | |
| ROE Annual % | 1.09 | 26.09 | 1.06 | 3.54 | 5.85 | |
| ROCE Annual % | 2.55 | 1.44 | 1.69 | 4.47 | 5.13 | |
| Total Debt to Total Equity Annual | 0.19 | 0.12 | 0.01 | 0.00 | 0.00 | |
| EBDIT Annual Margin % | 21.42 | 14.79 | 14.28 | 22.81 | 24.52 |
| Indicator | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Graph |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Qtr Revenue cr | 3965.70 | 4519.20 | 3620.20 | 3516.10 | 3928.80 | 3019.70 | 2384.20 | 2217.40 | 2476.10 | 2222.50 | 1945.30 | |
| Operating Expenses Qtr | 3001.20 | 3026.90 | 2720.70 | 2708.20 | 2776.60 | 2296.80 | 1849.00 | 1740.10 | 1816.90 | 1686.00 | 1394.60 | |
| Operating Profit Qtr | 915.90 | 926.80 | 741.60 | 714.40 | 997.30 | 644.30 | 470.70 | 399.40 | 591.90 | 488.20 | 445.80 | |
| EBIDT Qtr Cr | 955.70 | 1513.50 | 875.50 | 807.90 | 1149.20 | 451.50 | 518.20 | 477.30 | 618.20 | 536.50 | 480.60 | |
| Depreciation Qtr | 407.00 | 414.50 | 389.30 | 358.00 | 363.70 | 301.10 | 230.80 | 217.50 | 212.20 | 205.70 | 201.50 | |
| Net Profit Qtr | 135.50 | 660.00 | 125.60 | 101.40 | 313.20 | -41.80 | 46.90 | 144.40 | 238.60 | 187.10 | 138.30 | |
| Basic EPS Qtr | 1.13 | 5.52 | 1.05 | 0.85 | 2.62 | -0.35 | 0.39 | 1.21 | 2.00 | 1.57 | 1.16 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total Revenue Annual | 15621.20 | 11550.10 | 8396.70 | 7360.30 | 6461.90 | |
| Operating Expenses Annual Cr | 11457.00 | 8662.50 | 6213.80 | 5453.20 | 4697.40 | |
| Operating Profit Annual | 3298.70 | 2511.70 | 1970.20 | 1652.60 | 1603.10 | |
| Operating Profit Margin Annual % | 21.12 | 21.75 | 23.46 | 22.45 | 24.81 | |
| Total Expenses Annual Cr | 14000.20 | 10194.60 | 7095.60 | 6226.00 | 5314.50 | |
| EBIDT Annual Cr | 4164.20 | 2887.60 | 2182.90 | 1907.10 | 1764.50 | |
| EBIDT Annual margin % | 26.66 | 25.00 | 26.00 | 25.91 | 27.31 | |
| Depreciation | 1568.80 | 1113.10 | 814.20 | 715.10 | 552.20 | |
| PAT Before ExtraOrdinary Items Annual Cr | 1382.00 | 810.00 | 978.50 | 925.40 | 899.80 | |
| Net Profit Annual | 1022.50 | 462.70 | 648.40 | 740.50 | 748.20 | |
| Basic EPS Annual | 8.54 | 3.87 | 5.42 | 6.19 | 6.30 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total ShareHolders Funds Annual | 19783.70 | 17866.90 | 8432.50 | 7531.00 | 6705.80 | |
| Minority Interest Liability Annual Cr | 5491.10 | 4621.90 | 1037.50 | 880.70 | 677.30 | |
| Total Non Current Liabilities Annual Cr | 15437.10 | 21043.30 | 7096.00 | 5804.60 | 3052.70 | |
| Total Current Liabilities Annual Cr | 15358.80 | 8510.70 | 3828.00 | 4210.10 | 4008.00 | |
| Total Capital Plus Liabilities Annual Cr | 56070.70 | 52042.80 | 20394.00 | 18522.30 | 14443.80 | |
| Fixed Assets Annual | 22264.50 | 20648.50 | 10653.00 | 9137.70 | 8140.70 | |
| Total Non Current Assets Annual | 40891.50 | 39708.80 | 12011.70 | 10921.90 | 9118.80 | |
| Total Current Assets Annual | 15179.20 | 12334.00 | 8382.30 | 7600.40 | 5325.00 | |
| Total Assets Annual | 56070.70 | 52042.80 | 20394.00 | 18522.30 | 14443.80 | |
| Contingent Liabilities plus Commitments Annual Cr | - | 1990.90 | 1585.00 | 1588.60 | 1489.90 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Cash from Operating Activity Annual | 2953.90 | 1852.50 | 1176.60 | 1159.70 | 1283.10 | |
| Cash from Investing Activity Annual | -1004.50 | -14281.80 | -1699.10 | -3624.70 | -1558.90 | |
| Cash from Financing Annual Activity | -2332.70 | 13048.70 | 242.10 | 2564.00 | 387.60 | |
| Net Cash Flow Annual | - | 619.40 | -280.40 | 99.00 | 111.80 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Book Value Per Share Annual | 210.52 | 187.31 | 78.87 | 70.09 | 61.52 | |
| ROE Annual % | 5.16 | 2.58 | 7.69 | 9.83 | 11.15 | |
| ROCE Annual % | 6.37 | 4.07 | 8.26 | 8.32 | 11.61 | |
| Total Debt to Total Equity Annual | 0.80 | 0.99 | 0.58 | 0.47 | 0.28 | |
| EBDIT Annual Margin % | 28.22 | 25.84 | 26.67 | 26.83 | 28.00 |
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|---|---|---|---|
| KIRAN MAZUMDAR SHAW | 40.36 | 74802429 | 0 | 0 |
| GLENTEC INTERNATIONAL | 19.76 | 74802431 | 0 | 0 |
| Name | Holding Percent | Holding Id |
|---|---|---|
| SBI CONTRA FUND | 2.74 | 74802437 |
| QUANT MUTUAL FUND - QUANT MOMENTUM FUND | 1.24 | 74802438 |
| LICI CHILD FORTUNE PLUS GROWTH FUND | 4.41 | 74802440 |
| Name | Holding Percent | Holding Id |
|---|---|---|
| ARUN SURESH CHANDAVARKAR | 1.1 | 74802454 |
| Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
|---|---|---|---|---|
| Jul 05, 2024 | 0.5 | FINAL | Jul 05, 2024 | Equity Share |
| Jul 07, 2023 | 1.5 | FINAL | Jul 07, 2023 | Equity Share |
| Jun 30, 2022 | 0.5 | FINAL | Jul 01, 2022 | Equity Share |
| Jul 18, 2019 | 0.5 | FINAL | Jul 19, 2019 | Equity Share |
| Jul 19, 2018 | 1 | FINAL | Jul 20, 2018 | Equity Share |
| Jul 20, 2017 | 1 | FINAL | - | Equity Share |
| Mar 17, 2016 | 5 | INTERIM | Mar 19, 2016 | Equity Share |
| Apr 09, 2015 | 5 | INTERIM | Apr 10, 2015 | Equity Share |
| Jul 10, 2014 | 5 | FINAL | - | Equity Share |
| Jul 11, 2013 | 7.5 | FINAL | - | Equity Share |
| Jul 05, 2012 | 5 | FINAL | - | Equity Share |
| Jul 07, 2011 | 3 | FINAL | - | Equity Share |
| May 05, 2011 | 1.5 | INTERIM | May 06, 2011 | Equity Share |
| Jul 08, 2010 | 3.5 | FINAL | - | Equity Share |
| Jul 13, 2009 | 3 | FINAL | - | Equity Share |
| Jul 03, 2008 | 5 | FINAL | - | Equity Share |
| Jun 28, 2007 | 3 | FINAL | - | Equity Share |
| Jun 29, 2006 | 2.5 | FINAL | - | Equity Share |
| Jun 29, 2005 | 2 | FINAL | - | Equity Share |
| Jul 01, 2004 | 1 | FINAL | - | Equity Share |
| Ex-Date | Split Ratio | Record Date |
|---|
| Ex-Date | Purpose | Notes |
|---|---|---|
| May 16, 2024 | Audited Results & Final Dividend | - |
| Feb 08, 2024 | Quarterly Results | - |
| Nov 10, 2023 | Quarterly Results | - |
| Aug 10, 2023 | Quarterly Results | - |
| May 23, 2023 | Audited Results & Final Dividend | - |
| Apr 26, 2023 | Others | To consider, Fund Raising. |
| Feb 14, 2023 | Quarterly Results | - |
| Nov 14, 2022 | Quarterly Results | - |
| Jul 27, 2022 | Quarterly Results | - |
| Apr 28, 2022 | Audited Results & Dividend | - |
| Jan 20, 2022 | Quarterly Results | - |
| Oct 21, 2021 | Quarterly Results | - |
| Jul 22, 2021 | Quarterly Results | - |
| Apr 28, 2021 | Audited Results & Final Dividend | - |
| Jan 21, 2021 | Quarterly Results | - |
| Oct 22, 2020 | Quarterly Results | - |
| Jul 23, 2020 | Quarterly Results | - |
| May 14, 2020 | Audited Results | - |
| Jan 23, 2020 | Quarterly Results | - |
| Oct 23, 2019 | Quarterly Results | - |
| Jul 25, 2019 | Quarterly Results | - |
| Apr 25, 2019 | Audited Results, Dividend & Bonus | - |
| Jan 24, 2019 | Quarterly Results | - |
| Oct 25, 2018 | Quarterly Results | - |
| Jul 26, 2018 | Quarterly Results | - |
| Apr 26, 2018 | Audited Results & Final Dividend | - |
| Jan 24, 2018 | Quarterly Results | - |
| Oct 26, 2017 | Quarterly Results | - |
| Jul 27, 2017 | Quarterly Results | - |
| Apr 27, 2017 | Audited Results, F. Dividend & Bonus | - |
| Jan 24, 2017 | Quarterly Results | - |
| Oct 20, 2016 | Quarterly Results | - |
| Jul 21, 2016 | Quarterly Results & Others | The Company will organize a conference call for analysts and investors on July 22, 2016. |
| Apr 26, 2016 | Audited Results | - |
| Mar 11, 2016 | Interim Dividend | - |
| Jan 21, 2016 | Quarterly Results | - |
| Oct 20, 2015 | Quarterly Results | - |
| Jul 23, 2015 | Quarterly Results | - |
| Apr 29, 2015 | Audited Results | - |
| Jan 22, 2015 | Quarterly Results | - |
| Oct 21, 2014 | Quarterly Results | - |
| Jul 24, 2014 | Quarterly Results | - |
| Apr 24, 2014 | Audited Results & Dividend | - |
| Jan 22, 2014 | Quarterly Results | - |
| Oct 24, 2013 | Quarterly Results | - |
| Jul 25, 2013 | Quarterly Results | - |
| Apr 25, 2013 | Audited Results & Dividend | - |
| Jan 24, 2013 | Quarterly Results | - |
| Oct 30, 2012 | Quarterly Results | - |
| Jul 25, 2012 | Quarterly Results & Merger | To Consider merger of Biocon Biopharmaceuticals Limited; a wholly owned subsidiary with the Company. |
| Apr 26, 2012 | Audited Results & Dividend | - |
| Jan 24, 2012 | Quarterly Results | - |
| Oct 19, 2011 | Quarterly Results | (Revised) |
| Jul 21, 2011 | Quarterly Results | - |
| Apr 28, 2011 | Aud. Results, Dividend & Intm. Dividend | - |
| Jan 20, 2011 | Quarterly Results | - |
| Oct 22, 2010 | Quarterly Results | - |
| Jul 23, 2010 | Quarterly Results | - |
| Apr 29, 2010 | Audited Results & Dividend | - |
| Jan 21, 2010 | Quarterly Results | - |
| Oct 22, 2009 | Quarterly Results | - |
| Jul 23, 2009 | Quarterly Results | - |
| Apr 28, 2009 | Audited Results & Dividend | - |
| Jan 21, 2009 | Quarterly Results | - |
| Jul 17, 2008 | Quarterly Results | - |
| Apr 22, 2008 | Aud. Results, Dividend & Bonus Issue | - |
| Jan 17, 2008 | Quarterly Results | - |
| Oct 18, 2007 | Quarterly Results | - |
| Jul 18, 2007 | Quarterly Results | - |
| Apr 19, 2007 | Accounts & Dividend | - |
| Jan 18, 2007 | Quarterly Results | - |
| Oct 18, 2006 | Quarterly Results | - |
| Jul 19, 2006 | Quarterly Results | - |
| Apr 20, 2006 | Accounts & Dividend | - |
| Jan 18, 2006 | Quarterly Results | - |
| Oct 19, 2005 | Quarterly Results | - |
| Jul 20, 2005 | Quarterly Results | - |
| Apr 20, 2005 | Dividend & Accounts | - |
| Jan 20, 2005 | Quarterly Results | - |
| Jul 14, 2004 | Accounts | - |
| May 14, 2004 | Accounts & Dividend | - |
| Ex-Date | Bonus Ratio | Record Date |
|---|---|---|
| Jun 12, 2019 | 1:1 | 2019-06-13 |
| Jun 15, 2017 | 2:1 | 2017-06-17 |
| Sep 11, 2008 | 1:1 | 2008-09-12 |
28 Jun 2024
BIOCON LTD. - 532523 - Communication To The Shareholders W.R.T. TDS On Final Dividend
Communication to shareholders
28 Jun 2024
BIOCON LTD. - 532523 - Meeting Conducted With Institutional Investors/ Research Analysts
Meeting conducted with institutional investors/research analysts.
27 Jun 2024
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation
26 Jun 2024
BIOCON LTD. - 532523 - Meeting Conducted With Institutional Investors/ Research Analysts
Meeting conducted with Institutional Investors/ Research analyst
24 Jun 2024
Biocon gets EMA's nod to make biosimilar cancer drug at Bengaluru
Bevacizumab is used to treat colon and rectal cancer, cervical cancer etc
24 Jun 2024
BIOCON LTD. - 532523 - Company Statement Dated June 24, 2024.
EMA approves Biocon Biologics'' New mAbs Facility in India and Renews GMP certifications for India and Malaysia sites.
22 Jun 2024
Biocon Gets Four Observations From US Drugs Regulator For Andhra Facility
The USFDA concluded a GMP inspection of the API facility on June 21, 2024.
20 Jun 2024
Biocon searches for partner to test generic Wegovy, Ozempic in China
Biocon's generics would join at least 15 other generics or biosimilars in development by Chinese drugmakers ahead of an expiry of patent protection on semaglutide
